Abstract
Hidradenitis suppurativa is a debilitating disorder that can be difficult to manage with current conventional treatment strategies. Given its association with proinflammatory cytokines there has been interest in the use of novel biological monoclonal antibodies. We describe our experience with the use of these agents in six patients in whom conventional treatment had failed, with promising response noted in some patients. A growing number of studies now highlight the efficacy of these agents.
Keywords:
biological therapy; hidradenitis suppurativa; monoclonal antibody.
© 2014 The Australasian College of Dermatologists.
MeSH terms
-
Adalimumab
-
Adolescent
-
Adult
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Biological Therapy*
-
Etanercept
-
Female
-
Hidradenitis Suppurativa / drug therapy*
-
Humans
-
Immunoglobulin G / therapeutic use
-
Infliximab
-
Male
-
Middle Aged
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Retrospective Studies
-
Severity of Illness Index
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Young Adult
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Adalimumab
-
Etanercept